In Q2 2026, Deep Track Capital held 65 positions worth $6.7B. They initiated 12 new positions and exited 97. Their largest holding was GH ($509.1M). Portfolio value grew +39.5% versus the prior quarter.
Frequently asked questions
What stocks did Deep Track Capital own in Q2 2026?
Deep Track Capital held 65 biotech stocks in their 13F portfolio in Q2 2026. Their top positions include GH, IMVT, GPCR, PCVX, ALNY. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Deep Track Capital's portfolio worth in Q2 2026?
Deep Track Capital's tracked biotech portfolio was worth $6.7B across 65 positions, with total assets under management of approximately $5B. Portfolio values are based on 13F filings with the SEC.
What did Deep Track Capital buy in Q2 2026?
Deep Track Capital initiated 12 new positions in Q2 2026, including COAG, UTHR, ALT, WGSWW, HROW and 7 more. They also increased 27 existing positions.
What did Deep Track Capital sell in Q2 2026?
Deep Track Capital fully exited 97 positions in Q2 2026, including ALEC, FATE, INSM, ALLK, PEPG and 92 more. They also trimmed 15 existing positions.
Is Deep Track Capital a biotech fund?
Greenwich-based life sciences investment advisor founded by David Kroin, who previously co-founded Great Point Partners. Invests across public and private biotech, pharmaceutical, and medical device companies with over 25 years of healthcare investment expertise driving concentrated, high-conviction positioning.
Want AI analysis, insider signals, and catalyst overlays for Deep Track Capital?
View latest Deep Track Capitalportfolio →